Lux Ventures and a joint venture between Novartis and Qualcomm are investing $6.5 million into Science 37, an upstart company that promises to make clinical trials more efficient by uniting stakeholders. Science 37's model relies on partnering with mobile nursing companies, patient advocacy groups and tech outfits to provide its clients with a single point of contact in the study startup phase. The idea is to quickly unite patients and sponsors to eliminate the recruitment delays that often plague clinical trials. More